RCUS Q1 2020 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+0.0% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$28M-1622.9% margin

Net Income

-$28M-1585.9% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

-82.1%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$176M

Total Liabilities

$36M

Stockholders' Equity

$141M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+0.0%
Gross Profit	$2M	$2M	+0.0%
Operating Income	-$28M	-$19M	-51.3%
Net Income	-$28M	-$18M	-57.1%